The Journal of Urology
Volume 171, Issue 2, Supplement , Pages S5-S9 , February 2004

Prostate Cancer Chemoprevention: An Overview of United States Trials

  • ALBAHA BARQAWI
    • ,
  • IAN M. THOMPSON
    • ,
  • E. DAVID CRAWFORD

      Affiliations

    • Corresponding Author InformationCorrespondence: Urologic Oncology Division, University of Colorado Health Sciences Center, 4200 East Ninth Ave., Mail Container C-324, Denver, Colorado 80262 (telephone: 303-315-5936; FAX: 303-315-0662).

REFERENCES 

  1. Jemal A , Murray T , Samuels A , Ghafoor A , Ward E , Thun MJ . Cancer statistics, 2003 . CA Cancer J Clin . 2003;53:5
  2. Ries LA , Eisner MP , Kosary CL , Hankey BF , Miller BA , Clegg L , et al.   SEER Cancer Statistics Review 1973–1998 . Bethesda, Maryland: National Cancer Institute; 2001;
  3. Gronberg H , Isaacs SD , Smith JR , Carpton JD , Bova GS , Freije D , et al.   Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus . JAMA . 1997;278:1251
  4. Steinmetz KA , Potter JD . Vegetables, fruit, and cancer. I. Epidemiology . Cancer Causes Control . 1991;2:325
  5. Krzystyniak KL . Current strategies for anticancer chemoprevention and chemoprotection . Acta Pol Pharm . 2002;59:473
  6. Thompson IM , Goodman PJ , Tangen CM , Lucia MS , Miller GJ , Ford LG , et al.   The influence of finasteride on the development of prostate cancer . N Engl J Med . 2003;349:215
  7. Thompson IM , Tangen C , Goodman P . The Prostate Cancer Prevention Trial: design, status, and promise . World J Urol . 2003;21:28
  8. Raghow S , Hooshdaran MZ , Katiyar S , Steiner MS . Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model . Cancer Res . 2002;62:1370
  9. Gaynor ML . Isoflavones and the prevention and treatment of prostate disease: is there a role? . Cleveland Clin J Med . 2003;70:203
  10. Moyad MA . Soy, disease prevention, and prostate cancer . Semin Urol Oncol . 1999;17:97
  11. Lamartiniere CA , Cotroneo MS , Fritz WA , Wang J , Mentor-Marcel R , Elgavish A . Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate . J Nutr . 2002;132(suppl.):552S
  12. Pollard M , Wolter W . Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet . Prostate . 2000;45:101
  13. Halliwell B . Free radicals and antioxidants: a personal view . Nutr Rev . 1994;52:253
  14. Ripple MO , Henry WF , Rago RP , Wilding G . Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells . J Natl Cancer Inst . 1997;89:40
  15. Christen WG , Gaziano JM , Hennekens CH . Design of Physicians’ Health Study II—a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials . Ann Epidemiol . 2000;10:125
  16. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group . N Engl J Med . 1994;330:1029
  17. Gann PH , Ma J , Giovannucci E , Willett W , Sacks FM , Hennekens CH , et al.   Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis . Cancer Res . 1999;59:1225
  18. Heber D , Lu QY . Overview of mechanisms of action of lycopene . Exp Biol Med . 2002;227:920
  19. Aust O , Ale-Agha N , Zhang L , Wollersen H , Sies H , Stahl W . Lycopene oxidation product enhances gap junctional communication . Food Chem Toxicol . 2003;41:1399
  20. Habermann H , Ray V , Habermann W , Prins GS . Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer . J Urol . 2001;166:2267
  21. Miller EC , Giovannucci E , Erdman JW , Bahnson R , Schwartz SJ , Clinton SK . Tomato products, lycopene, and prostate cancer risk . Urol Clin North Am . 2002;29:83
  22. Clark LC , Dalkin B , Krongrad A , Combs GF , Turnbull BW , Slater FH , et al.   Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial . Br J Urol . 1998;81:730
  23. Virtamo J , Pietinen P , Huttunen JK , Korhonen P , Malila N , Virtanen MJ , et al.   Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up . JAMA . 2003;290:476
  24. Chan JM , Stampfer MJ , Ma J , Rimm EB , Willett WC , Giovannucci EL . Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States . Cancer Epidemiol Biomarkers Prev . 1999;8:893
  25. Combs GF , Clark LC , Turnbull BW . Reduction of cancer risk with an oral supplement of selenium . Biomed Environ Sci . 1997;10:227
  26. Klein EA , Thompson IM , Lippman SM , Goodman PJ , Albanes D , Taylor PR , et al.   SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial . J Urol . 2001;166:1311
  27. Klein EA , Lippman SM , Thompson IM , Goodman PJ , Albanes D , Taylor PR , et al.   The selenium and vitamin E cancer prevention trial . World J Urol . 2003;21:21
  28. Gupta S , Srivastava M , Ahmad N , Bostwick DG , Mukhtar H . Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma . Prostate . 2000;42:73
  29. Madaan S , Abel PD , Chaudhary KS , Hewitt R , Stott MA , Stamp GW , et al.   Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment . BJU Int . 2000;86:736
  30. Lee LM , Pan CC , Cheng CJ , Chi CW , Liu TY . Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia . Anticancer Res . 2001;21:1291
  31. Kamijo T , Sato T , Nagatomi Y , Kitamura T . Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines . Int J Urol . 2001;8(suppl.):S35
  32. Johnson AJ , Song X , Hsu A , Chen C . Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells . Adv Enzyme Regul . 2001;41:221
  33. Fujita H , Koshida K , Keller ET , Takahashi Y , Yoshimito T , Namiki M , et al.   Cyclooxygenase-2 promotes prostate cancer progression . Prostate . 2002;53:232
  34. Liu XH , Kirschenbaum A , Yao S , Lee R , Holland JF , Levine AC . Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo . J Urol . 2000;164:820
  35. Pan Y , Zhang JS , Gazi MH , Young CY . The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells . Cancer Epidemiol, Biomarkers Prev . 2003;12:769
  36. Moran EM . Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks . J Environ Pathol Toxicol Oncol . 2002;21:193
  37. Sokoloff MH , Tso CL , Kaboo R , Taneja S , Pang S , de Kernion JB , et al.   In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines . Cancer . 1996;77:1862
  38. Simons JW , Mikhak B , Chang JF , DeMarzo AM , Carducci MA , Lim M , et al.   Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer . Cancer Res . 1999;59:5160
  39. DeWeese TL , Hruszkewycz AM , Marnett LJ . Oxidative stress in chemoprevention trials . Urology . 2001;57(suppl.):137
  40. Schwartz GG , Hulka BS . Is vitamin D deficiency a risk factor for prostate cancer? . Anticancer Res . 1990;10:1307
  41. Miller GJ , Stapleton GE , Ferrara JA , Lucia MS , Pfister S , Hedlund TE , et al.   The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3 . Cancer Res . 1992;52:515
  42. Miller GJ . Vitamin D and prostate cancer: biologic interactions and clinical potentials . Cancer Metastasis Rev . 1998;17:353
  43. Konety BR , Getzenberg RH . Vitamin D and prostate cancer . Urol Clin North Am . 2002;29:95
  44. Walczak J , Wood H , Wilding G , Williams TJ , Bishop CW , Carducci M . Prostate cancer prevention strategies using antiproliferative or differentiating agents . Urology . 2001;57:81
  45. Le Marchand L , Kolonel LN , Wilkens LR , Myers BC , Hirohata T . Animal fat consumption and prostate cancer: a prospective study in Hawaii . Epidemiology . 1994;5:276
  46. Schuurman AG , van den Brandt PA , Dorant E , Goldbohm RA . Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study . Br J Cancer . 1999;80:1107

PII: S0022-5347(05)62508-6

doi: 10.1097/01.ju.0000108141.36320.59

The Journal of Urology
Volume 171, Issue 2, Supplement , Pages S5-S9 , February 2004

Article Tools